Phase 1 repeated dosing of Voriconazole Inhalation Powder of up to 80 mg/dose in healthy subjects for direct-to-lung delivery of voriconazole for Invasive Pulmonary Aspergillosis AUSTIN, Texas --(BUSINESS WIRE)--Jul. 30, 2020-- TFF Pharmaceuticals, Inc.

Scientists at The University of Texas at Austin report on the use of Thin Film Freezing technology to deliver remdesivir through dry powder inhalation AUSTIN, Texas --(BUSINESS WIRE)--Jul. 29, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on